Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background and objectives: In trials of people with type 2 diabetes, albuminuria reduction with renin-angiotensin system inhibitors is associated with lower risks of cardiovascular events and CKD progression. We tested whether progression or remission of microalbuminuria is associated with cardiovascular and renal risk in a well characterized cohort of type 1 diabetes. Design, setting, participants, & measurements: We studied 1441 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Albumin excretion rate (AER) was quantified annually or biennially for up to 30 years. For each participant, albuminuria status was defined over time as normoalbuminuria (AER continuously <30 mg/d), sustained microalbuminuria (AER, 30–299 mg/d on two consecutive visits), macroalbuminuria (AER≥300 mg/d), or remitted microalbuminuria (transition from sustained microalbuminuria to AER<30 mg/d on two consecutive visits). We tested associations of time-updated albuminuria status with adjudicated clinical cardiovascular events, the development of reduced GFR (<60 ml/min per 1.73 m 2 on two consecutive visits), and subclinical cardiovascular disease. Results: At least one cardiovascular event occurred in 184 participants, and 98 participants developed reduced eGFR. Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were each associated with higher risk of cardiovascular events (adjusted hazard ratios [HRs] and 95% confidence intervals [95% CIs]: 1.79 [1.13 to 2.85], 2.62 [1.68 to 4.07], and 2.65 [1.68 to 4.19], respectively) and reduced eGFR (adjusted HRs [95% CIs], 5.26 [2.43 to 11.41], 4.36 [1.80 to 10.57], and 54.35 [30.79 to 95.94], respectively). Compared with sustained microalbuminuria, remission to normoalbuminuria was not associated with reduced risk of cardiovascular events (adjusted HR, 1.33; 95% CI, 0.68 to 2.59) or reduced eGFR (adjusted HR, 1.75; 95% CI, 0.56 to 5.49). Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were associated with greater carotid intima-media thickness, and macroalbuminuria was associated with a greater degree of coronary artery calcification. Conclusions: In type 1 diabetes, microalbuminuria and macroalbuminuria are associated with higher risks of cardiovascular disease and reduced eGFR, but achieving a remission of established microalbuminuria to normoalbuminuria does not appear to improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have reported inconsistent results (43,44).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In randomized clinical trials, it has taken a number of years for bene fi ts of intensive glycemic control to manifest as improved clinical outcomes. 190,191,234,245,246,248,256”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [234]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in clinical trials, targeting lower HbA1c levels has reduced the rates of chronic diabetes complications in patients with T1D 190,232 -238 or T2D. 239 -246”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [234]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have overall reported cardiovascular and kidney outcome benefits (9,45,46).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In type 1 diabetes, remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have reported inconsistent results (43,44).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298 · cited 1×
“Current smoking 266 (18) 109 (26) 37 (22) 49 (27) Body mass index, kg/m(2) 23.”
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975 · cited 2×
“For example, in the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan study, all participants had macroalbuminuria at baseline, and RAS inhibitor–induced reductions in albuminuria were associated with lower subsequent CVD and renal risk (5,6).”
BackgroundRegression of Microalbuminuria in Type 1 Diabetes
Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021835 · Cited by 801
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750 · cited 1×
“For example, in the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan study, all participants had macroalbuminuria at baseline, and RAS inhibitor–induced reductions in albuminuria were associated with lower subsequent CVD and renal risk (5,6).”
BackgroundThe Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
The Diabetes Control and Complications Trial Research Group (1994) · Retina · doi:10.1097/00006982-199414030-00022 · Cited by 551
The 30-Year Natural History of Type 1 Diabetes Complications
Pambianco, G., Costacou, T., Ellis, D., Becker, D. J., Klein, R., & Orchard, T. J. (2006) · Diabetes · doi:10.2337/db05-1423 · Cited by 493
Self-citationde Boer, I. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.16 · Cited by 351
Orchard, T. J., Secrest, A. M., Miller, R. G., & Costacou, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1860-3 · Cited by 313 · cited 1×
“manifestations of diabetic kidney disease accounted statistically for all the excess mortality in two large type 1 diabetes cohorts (23,24).”
BackgroundSelf-citationLevey, A. S., Cattran, D., Friedman, A., Miller, W. G., Sedor, J., Tuttle, K., Kasiske, B., & Hostetter, T. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.04.029 · Cited by 298
Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
Schmieder, R. E., Mann, J. F. E., Schumacher, H., Gao, P., Mancia, G., Weber, M. A., McQueen, M., Koon, T., & Yusuf, S. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010091001 · Cited by 270
Cleary, P. A., Orchard, T. J., Genuth, S., Wong, N. D., Detrano, R., Backlund, J.-Y. C., Zinman, B., Jacobson, A., Sun, W., Lachin, J. M., et al. (2006) · Diabetes · doi:10.2337/db06-0653 · Cited by 264 · cited 3×
“0 versus $0) using multivariable logistic regression and with the presence and extent of CAC using Tobit regression (19).”
MethodSelf-citationde Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View
Lambers Heerspink, H. J., & Gansevoort, R. T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11511114 · Cited by 168
Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus
de Boer, I. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.2 · Cited by 126
Polak, J. F., Backlund, J.-Y. C., Cleary, P. A., Harrington, A. P., O’Leary, D. H., Lachin, J. M., Nathan, D. M., & for the DCCT/EDIC Research Group (2011) · Diabetes · doi:10.2337/db10-0296 · Cited by 125 · cited 1×
“(IMT) measured at EDIC study year 12 (January 5, 2004– August 17, 2005) (19,20).”
Self-citationSteffes, M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.042143 · Cited by 125 · cited 1×
“manifestations of diabetic kidney disease accounted statistically for all the excess mortality in two large type 1 diabetes cohorts (23,24).”
BackgroundSelf-citationRenal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
de Boer, I. H., Afkarian, M., Rue, T. C., Cleary, P. A., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., & Zinman, B. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013091004 · Cited by 100
Self-citationYounes, N., Cleary, P. A., Steffes, M. W., de Boer, I. H., Molitch, M. E., Rutledge, B. N., Lachin, J. M., & Dahms, W. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07901109 · Cited by 61
Self-citationAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Fried, L. F., & Lewis, J. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
de Zeeuw, D., Remuzzi, G., & Parving, H. H. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.11.013 · Cited by 25
CHANGES IN ALBUMINURIA PREDICT MORTALITY AND MORBIDITY IN PATIENTS WITH VASCULAR DISEASE: PS.3.04
Schmieder, R., Mann, J., Schumacher, H., Gao, P., Mancia, G., Weber, M., McQueen, M., Teo, K., & Yusuf, S. (2010) · Journal of Hypertension · doi:10.1097/01.hjh.0000384007.86281.82
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Self-citation
Metadata
- Authors
- de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., Zinman, B., & for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington;
- George Washington University (US)
- Northwestern University (US)
- University of Pittsburgh (US)
- Hospital for Sick Children (CA)
- University Health Network (CA)
- University of Minnesota (US)
- Mount Sinai Hospital (CA)
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-10-24
- Volume
- 11
- Issue
- 11
- Pages
- 1969-1977
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5108190
- OpenAlex
- W2537149664
- Semantic Scholar
- 24c112fdab228e526acf749547e57594378cc73a
- Cited by
- 114
- References
- 26
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 11 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 23 · 2017: 14 · 2016: 4
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01dk094157-13)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, R01DK088762, P30DK017047)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- albuminuria, microalbuminuria, type 1 diabetes, urinary albumin excretion rate, cardiovascular events, reduced eGFR, chronic kidney disease progression, macroalbuminuria, subclinical cardiovascular disease, DCCT/EDIC, renin-angiotensin system inhibitors, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy
- MeSH terms
- Adult, Albuminuria, Angina Pectoris, Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Male, Middle Aged, Myocardial Infarction, Randomized Controlled Trials as Topic, Stroke, Renal Insufficiency, Chronic, Young Adult, Carotid Intima-Media Thickness, Vascular Calcification, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.